Collaborative study to evaluate Kubota Glass technology in children with myopia
Click Here to Manage Email Alerts
In a new research agreement with China Medical University Hsinchu Hospital, Kubota Vision will evaluate Kubota Glass technology in myopic children in Taiwan.
The study will examine the effectiveness of the technology in children with myopia compared with a 0.01% low-dose atropine control group, as well as an arm investigating a potential synergistic effect of combination therapy, according to a company press release.
Ying-Shan Chen, MD, chief of ophthalmology at China Medical University Hsinchu Hospital, will lead the study.
“As recent studies have shown limited effectiveness in some patient populations with 0.01% atropine monotherapy, the use of combination treatments for slowing the progression of myopia has been suggested as a next step for evaluating optical strategies such as specialized glasses,” Ryo Kubota, MD, PhD, chairman, president and CEO of Kubota Vision, said in the release. “We are excited to explore this important area with Dr. Chen, who is one of the foremost experts in myopia treatment, as we continue to work toward our goal of revolutionizing myopia therapy around the world.”
Read more about
Click Here to Manage Email Alerts